1. The instrument
The GAD-7 is a self-report screening instrument designed to identify probable generalized anxiety disorder in primary-care and general-population settings. It was developed by Robert L. Spitzer, Kurt Kroenke, Janet B. W. Williams, and Bernd Löwe in 2006 and published in Archives of Internal Medicine. It is one of the most widely used brief anxiety screens.
The instrument was developed by starting with a 13-item pool derived from DSM-IV criteria for GAD plus other anxiety measure items. The 7 items with the highest correlation to total score were selected, prioritizing brevity and clinical utility for primary-care contexts where screening time is limited.
The GAD-7 is published with permissive licensing — Pfizer (the original sponsor) granted explicit permission to reproduce, translate, display, or distribute the instrument without charge. This contrasts with several other anxiety instruments that carry commercial licensing fees.
2. The 7 items
Over the last 2 weeks, how often have you been bothered by the following problems?
| # | Item | Score range |
|---|---|---|
| 1 | Feeling nervous, anxious, or on edge | 0–3 |
| 2 | Not being able to stop or control worrying | 0–3 |
| 3 | Worrying too much about different things | 0–3 |
| 4 | Trouble relaxing | 0–3 |
| 5 | Being so restless that it is hard to sit still | 0–3 |
| 6 | Becoming easily annoyed or irritable | 0–3 |
| 7 | Feeling afraid as if something awful might happen | 0–3 |
Response options: 0 = Not at all, 1 = Several days, 2 = More than half the days, 3 = Nearly every day. Total score range: 0–21.
3. Scoring and severity bands
The GAD-7 total score is the simple sum of the 7 item responses. There are no reverse-coded items and no weighting. Standard severity bands per Spitzer et al. 2006:
- 0–4 Minimal anxiety. Symptoms unlikely to indicate clinically significant anxiety.
- 5–9 Mild anxiety. Some symptoms present, subthreshold for GAD.
- 10–14 Moderate anxiety. Probable GAD per the standard cutoff.
- 15–21 Severe anxiety. High symptom burden; professional consultation strongly recommended.
The standard published cutoff is ≥10 (Spitzer et al. 2006). NHS Talking Therapies (formerly IAPT, Improving Access to Psychological Therapies) uses the GAD-7 as a routine outcome measure and counts a score of 8 or more as a clinical case. Plummer et al. 2016 meta-analysis suggested cutoff ≥8 may optimize sensitivity-specificity in some contexts; the tool uses ≥10 because it is the most-cited and clinically-established cutpoint.
4. Validation evidence
| Property | Value | Source |
|---|---|---|
| Sensitivity at cutoff ≥10 | 89% | Spitzer et al. 2006 |
| Specificity at cutoff ≥10 | 82% | Spitzer et al. 2006 |
| Cronbach's α (internal consistency) | 0.92 | Spitzer et al. 2006, n=2,740 |
| Test-retest reliability (1-week) | ICC 0.83 | Spitzer et al. 2006 |
| General population mean | 3.0 (SD 3.4) | Löwe et al. 2008, n=5,030 |
The GAD-7 has been translated into many languages. Validation studies in non-Western populations generally support the instrument's reliability, though specific cutoff values may differ by population.
5. Limitations of the screen
- Not diagnostic. The GAD-7 is a screen, not a diagnosis. A score of 10+ is a strong signal that anxiety symptoms warrant clinical attention, but only a qualified professional can diagnose GAD via DSM-5 or ICD-11 clinical interview.
- Captures last 2 weeks only. Anxiety naturally fluctuates with life events. A snapshot during a stressful period may overstate; a snapshot during a calm period may understate.
- Sensitive to multiple anxiety disorders. Per Kroenke et al. 2007, the GAD-7 also screens panic disorder (sens 74%), social anxiety disorder (sens 72%), and PTSD (sens 66%) at ≥10. Useful for transdiagnostic screening but a limitation for GAD-specific case finding.
- Self-report dependent. Self-criticism, alexithymia, denial, recall bias, or aspirational responding can distort scores.
- Specificity drops in psychiatric samples. In a heterogeneous psychiatric sample (n=1,082), Beard & Björgvinsson 2014 found poor specificity and a high false-positive rate for specific anxiety disorders.
- Cultural variation. The instrument was developed in US primary care. Cultural expression of anxiety varies, and somatic-vs-cognitive emphasis differs across cultures.
6. Frequently asked questions
What is the GAD-7?
The GAD-7 is a validated 7-item self-report screening instrument for generalized anxiety disorder, developed by Spitzer, Kroenke, Williams, and Löwe in 2006 and published in Archives of Internal Medicine. It is one of the most widely used brief anxiety screens.
How does the GAD-7 score work?
Each of the 7 items is scored 0-3 based on frequency over the past 2 weeks (0=not at all, 1=several days, 2=more than half the days, 3=nearly every day). Total scores range from 0 to 21. Standard severity bands per Spitzer 2006: 0-4 minimal, 5-9 mild, 10-14 moderate, 15-21 severe.
What does a score of 10 mean?
A score of 10 or higher is the standard cutoff for probable generalized anxiety disorder. At this threshold, the GAD-7 has 89% sensitivity and 82% specificity per Spitzer 2006 (n=965 patients with structured diagnostic interviews). NHS Talking Therapies (formerly IAPT) uses the GAD-7 as a routine outcome measure and counts a score of 8 or more as a clinical case.
Does the GAD-7 only screen for GAD?
Although designed for GAD, the GAD-7 also screens reasonably well for panic disorder (sensitivity 74%), social anxiety disorder (sensitivity 72%), and PTSD (sensitivity 66%) at the standard ≥10 cutoff per Kroenke et al. 2007. A high score indicates 'anxiety symptoms present' rather than 'GAD specifically.' This is a feature for transdiagnostic screening but a limitation for GAD-specific case finding.
Is the GAD-7 reliable?
Yes. Cronbach's α = 0.92 in the original validation (Spitzer 2006) and 0.89 in a German general-population sample (Löwe 2008), and a large psychiatric sample also showed good internal consistency (Beard & Björgvinsson 2014). Test-retest reliability is intraclass correlation 0.83 over one week.
Can the GAD-7 diagnose GAD?
No. The GAD-7 is a screening instrument, not a diagnostic tool. Diagnosis of GAD requires a clinical interview by a qualified mental health professional using DSM-5 or ICD-11 criteria. The screen identifies who should be evaluated further; the evaluation establishes the diagnosis.
Where can I take a GAD-7?
The free LifeByLogic Anxiety Test uses the seven GAD-7 items and the standard severity bands, and adds a symptom profile, an archetype and suggested pathways. Like the GAD-7 itself, it is a screen, not a diagnosis, and it shows crisis resources at high scores.
7. Related concepts
How to cite this entry
This entry is intended as a citable scholarly reference. Choose the format that matches your context. The retrieval date should reflect when you accessed the page, which may differ from the entry’s last-reviewed date shown above.
APA 7th edition
LifeByLogic. (2026). GAD-7 Screener — instrument structure, scoring, and validation. https://lifebylogic.com/glossary/gad-7-screener/MLA 9th edition
LifeByLogic. "GAD-7 Screener — instrument structure, scoring, and validation." LifeByLogic, 25 Oct. 2026, https://lifebylogic.com/glossary/gad-7-screener/.Chicago (author-date)
LifeByLogic. 2026. "GAD-7 Screener — instrument structure, scoring, and validation." October 25. https://lifebylogic.com/glossary/gad-7-screener/.BibTeX
@misc{lblgad7screener2026,
author = {{LifeByLogic}},
title = {GAD-7 Screener — instrument structure, scoring, and validation},
year = {2026},
month = {oct},
publisher = {LifeByLogic},
url = {https://lifebylogic.com/glossary/gad-7-screener/},
note = {Accessed: 2026-10-25}
}8. References
- Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine, 166(10), 1092–1097. doi.org/10.1001/archinte.166.10.1092
- Löwe, B., Decker, O., Müller, S., et al. (2008). Validation and standardization of the GAD-7 in the general population. Medical Care, 46(3), 266–274. doi.org/10.1097/MLR.0b013e318160d093
- Hinz, A., Klein, A. M., Brähler, E., et al. (2017). Psychometric evaluation of the GAD-7. Journal of Affective Disorders, 210, 338–344. doi.org/10.1016/j.jad.2016.12.012
- Plummer, F., Manea, L., Trepel, D., & McMillan, D. (2016). Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. General Hospital Psychiatry, 39, 24–31. doi.org/10.1016/j.genhosppsych.2015.11.005
- Kroenke, K., Spitzer, R. L., Williams, J. B. W., Monahan, P. O., & Löwe, B. (2007). Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Annals of Internal Medicine, 146(5), 317–325. doi.org/10.7326/0003-4819-146-5-200703060-00004
- Beard, C., & Björgvinsson, T. (2014). Beyond generalized anxiety disorder: psychometric properties of the GAD-7 in a heterogeneous psychiatric sample. Journal of Anxiety Disorders, 28(6), 547–552. doi.org/10.1016/j.janxdis.2014.06.002